Luis Corrales - Concepedia

Author

Luis Corrales

Instituto Nacional de Cancerología ORCID

Also Known As

Claudio Martín, Corrales, L., Jorge Otero, L Corrales, L. Corrales, L. Corrales-Rodriguez, L. Corrales–Rodriguez, LUIS CORRALES, Luis A Corrales, Luis A. Corrales

182

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Instituto Nacional de Cancerología Foundation for Clinical and Applied Cancer Research Instituto Alexander Fleming Universidad El Bosque Instituto Nacional de Enfermedades Neoplásicas

About

Luis Corrales is an author at Instituto Nacional de Cancerología specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1.8K
2	Health Sciences	2	2	544
3	Cell Biology	1	1	33
4	Emergency Medicine	1	1	15
5	Genomic Medicine	1	1	23

Luis Corrales

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, The Lancet Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma	2023	415
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial Christopher J. Sweeney, Sergio Bracarda, Cora N. Sternberg, The Lancet UrologyOncologyGenitourinary CancerMedicineClinical Trials	2021	313
Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP) Óscar Arrieta, Andrés F. Cardona, Claudio Martín, Journal of Thoracic Oncology Kras MutationsOncologyCancer EpidemiologyMedicinePathology	2015	190
Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations Jian Carrot‐Zhang, Giovanny Soca‐Chafre, Nick Patterson, Cancer Discovery	2020	142
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer Óscar Arrieta, Andrés F. Cardona, Luis Corrales, Lung Cancer MedicineRare Egfr MutationsPathologyBronchial NeoplasmCancer Treatment	2014	84
EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP) Andrés F. Cardona, Leonardo Rojas, Zyanya Lucía Zatarain-Barrón, Lung Cancer Tumor BiologyMedicinePathologyBronchial NeoplasmMolecular Oncology	2018	60
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) Alejandro Ruíz-Patiño, Óscar Arrieta, Andrés F. Cardona, Thoracic Cancer	2019	60
Pluripotent Nontumorigenic Adipose Tissue-Derived Muse Cells have Immunomodulatory Capacity Mediated by Transforming Growth Factor-β1 María L. Gimeno, Florencia Fuertes, Andres E. Barcala Tabarrozzi, Stem Cells Translational Medicine	2016	59
Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study Luis Corrales, Denis Soulières, Xiaoduan Weng, Thrombosis Research Lung Cancer-associated ThrombosisSomatic VariantOncogenic AgentMedicinePathology	2013	58

Page 1